Sökning: WFRF:(Swedberg Karl)
> (2005-2009) >
Liver function abno...
Liver function abnormalities and outcome in patients with chronic heart failure: data from the Candesartan in Heart Failure: Assessment of Reduction in Mortality and Morbidity (CHARM) program
-
Allen, L. A. (författare)
-
Felker, G. M. (författare)
-
Pocock, S. (författare)
-
visa fler...
-
McMurray, J. J. (författare)
-
Pfeffer, M. A. (författare)
-
- Swedberg, Karl, 1944 (författare)
- Gothenburg University,Göteborgs universitet,Institutionen för medicin, avdelningen för akut och kardiovaskulär medicin,Institute of Medicine, Department of Emergeny and Cardiovascular Medicine
-
Wang, D. (författare)
-
Yusuf, S. (författare)
-
Michelson, E. L. (författare)
-
Granger, C. B. (författare)
-
visa färre...
-
(creator_code:org_t)
- 2009-01-28
- 2009
- Engelska.
-
Ingår i: Eur J Heart Fail. - : Wiley. - 1388-9842. ; 11:2, s. 170-7
- Relaterad länk:
-
https://onlinelibrar...
-
visa fler...
-
https://gup.ub.gu.se...
-
https://doi.org/10.1...
-
visa färre...
Abstract
Ämnesord
Stäng
- AIMS: The prevalence and importance of liver function test (LFT) abnormalities in a large contemporary cohort of heart failure patients have not been systematically evaluated. METHODS AND RESULTS: We characterized the LFTs of 2679 patients with symptomatic chronic heart failure from the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity program (CHARM). We used multivariable modelling to assess the relationships between baseline LFT values and long-term outcomes. Liver function test abnormalities were common in patients with chronic heart failure, ranging from alanine aminotransferase elevation in 3.1% of patients to low albumin in 18.3% of patients; total bilirubin was elevated in 13.0% of patients. In multivariable analysis, elevated total bilirubin was the strongest LFT predictor of adverse outcome for both the composite outcome of cardiovascular death or heart failure hospitalization (HR 1.21 per 1 SD increase, P<0.0001) and all-cause mortality (HR 1.19 per 1 SD increase, P<0.0001). Even after adjustment for other variables, elevated total bilirubin was one of the strongest independent predictors of poor prognosis (by global chi-square). CONCLUSION: Bilirubin is independently associated with morbidity and mortality. Changes in total bilirubin may offer insight into the underlying pathophysiology of chronic heart failure.
Ämnesord
- MEDICIN OCH HÄLSOVETENSKAP -- Klinisk medicin -- Kardiologi (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Clinical Medicine -- Cardiac and Cardiovascular Systems (hsv//eng)
Nyckelord
- Aged
- Alanine Transaminase/blood
- Alkaline Phosphatase/blood
- Aspartate Aminotransferases/blood
- Bilirubin/blood
- Chronic Disease
- Female
- Heart Failure/complications/mortality/*physiopathology
- Hospitalization
- Humans
- Liver Diseases/complications/diagnosis
- *Liver Function Tests
- Male
- Middle Aged
- Prognosis
- Proportional Hazards Models
- Serum Albumin/analysis
- Ventricular Function
- Left
Publikations- och innehållstyp
- ref (ämneskategori)
- art (ämneskategori)
Hitta via bibliotek
Till lärosätets databas
- Av författaren/redakt...
-
Allen, L. A.
-
Felker, G. M.
-
Pocock, S.
-
McMurray, J. J.
-
Pfeffer, M. A.
-
Swedberg, Karl, ...
-
visa fler...
-
Wang, D.
-
Yusuf, S.
-
Michelson, E. L.
-
Granger, C. B.
-
visa färre...
- Om ämnet
-
- MEDICIN OCH HÄLSOVETENSKAP
-
MEDICIN OCH HÄLS ...
-
och Klinisk medicin
-
och Kardiologi
- Artiklar i publikationen
-
Eur J Heart Fail
- Av lärosätet
-
Göteborgs universitet